Hearing loss may be a risk factor for developing Parkinson’s disease, or may be an early warning sign of the neurodegenerative condition, according to a new study from the U.K. Specifically, the study found that for every 10 decibels of hearing impairment, the risk of developing Parkinson’s increased by…
The Michael J. Fox Foundation (MJFF) has launched this year’s “Parkinson’s IQ + You,” a series of in-person events to help patients and care partners effectively navigate the challenges of Parkinson’s disease. Launched in 2019, the free event series seeks to educate people about the disease, including…
A Phase 2 clinical trial of AB-1005, AskBio’s gene therapy for Parkinson’s disease, has randomly assigned its first participants to different treatment groups, the company has announced. Called REGENERATE-PD (NCT06285643), the trial is expected to enroll about 87 adults with moderate Parkinson’s, ages 45 to 75, who…
Medtronic’s BrainSense adaptive deep brain stimulation (aDBS) system and electrode identifier have received CE Mark approval in the European Union (EU) and the U.K. for the management of Parkinson’s disease. CE Mark approval indicates that the European Commission, the EU’s regulatory body, considered Medtronic’s system to meet…
A research project that’s designed to help improve communication for people with Parkinson’s disease by focusing on listener training has been awarded a $2.6 million, five-year grant from the National Institutes of Health (NIH). The funding will help researchers implement a structured listener training program and test its effectiveness in…
Mytos and Aspen Neuroscience are teaming up to automate the manufacture of autologous dopaminergic neuronal precursor cells (DNPCs) for ANPD001, Aspen’s experimental cell therapy program for Parkinson’s disease. As part of the agreement, Aspen will integrate Mytos’ iDEM automated cell culture technology into its new manufacturing…
The American Parkinson Disease Association (APDA) has announced that it will host its third annual, free, virtual conference for people with Parkinson’s disease and their caregivers on Feb. 19-20. The program is scheduled to run from 12 p.m. to 4 p.m. ET each day. Tailored to “educate, empower…
Treatment with Vyalev (foscarbidopa and foslevodopa) eased motor symptoms and sleep disturbances in a 50-year-old man with Parkinson’s disease and a history of dream enactment behavior, according to a case report from Japan. Dream enactment behavior is a sign of rapid eye movement (REM) sleep disorder, in which…
People with neurodegenerative diseases like Parkinson’s disease or dementia are more vulnerable to heat-related complications than those without these conditions, according to a commentary by two neurologists. Medical providers should be trained to understand how heat waves can affect these people, the viewpoint advised. It was co-written by Indu…
Adaptive deep brain stimulation (aDBS) resulted in long-lasting relief from bradykinesia and walking difficulties in a 61-year-old Parkinson’s disease patient, whose quality of life also improved, researchers wrote in a case report about the man. Unlike conventional DBS (cDBS), where electric brain stimulation is constant or adjusted manually…
Get regular updates to your inbox.
